SBio drug shows promise for symptom and spleen reduction for myelofibrosis patients

December 2010

Data from SBio's ongoing clinical trial for their JAK2 Inhibitor SB1518 was reported at the recent annual meeting of the American Society of Hematology. Dr. Srdan Verstovsek reported that thus far 57% of patients enrolled had experience reduction in spleen as well as reduction in constitutional symptoms of myelofibrosis. The drug was reported to also be well-tolerated.

For the complete article click here.